Glybera | search
Click here to view Glybera news from 60+ newspapers.
Bookmark or Share- After Glybera's withdrawal, what's next for gene therapy?Five years after it became the first gene therapy to win approval in Europe, Amsterdam-based uniQure's Glybera (alipogene tiparvovec) is being withdrawn, not because of safety issues, but...
- With its launch fizzling out, UniQure gives up on $1M+ gene therapy GlyberaAfter struggling for years to make a commercial success out of Glybera, the world’s first approved gene therapy, uniQure is calling it quits on the ultraexpensive treatment.
- Glybera - Alipogene tiparvovec - Gene Therapy NetGlybera (Alipogene tiparvovec) is a gene therapy treatment designed to reverse lipoprotein lipase deficiency (LPLD), a rare inherited disorder which can cause severe pancreatitis.
- The World’s Most Expensive Medicine Is Being Pulled from the MarketThe drug, Glybera, was the most expensive prescription medication in history at $1 million for a one-time round of injections (see “The World’s Most Expensive Medicine Is a Bust”). It contains...
- Glybera (alipogene tiparvovec) for Treatment of Lipoprotein Lipase ...Glybera (alipogene tiparvovec) is a gene therapy indicated for the treatment Lipoprotein Lipase Deficiency (LPLD). It was developed by Amsterdam Molecular Therapeutics (AMT), which was acquired by uniQure in April 2012.
More
